PT - JOURNAL ARTICLE AU - Coscia, Claudia AU - Gill, Dipender AU - Benítez, Raquel AU - Pérez, Teresa AU - Malats, Núria AU - Burgess, Stephen TI - Avoiding bias in Mendelian randomization when stratifying on a collider AID - 10.1101/2021.08.17.21262178 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.17.21262178 4099 - http://medrxiv.org/content/early/2021/08/24/2021.08.17.21262178.short 4100 - http://medrxiv.org/content/early/2021/08/24/2021.08.17.21262178.full AB - Background Mendelian randomization (MR) uses genetic variants as instrumental variables to investigate the causal effect of a risk factor on an outcome. A collider is a variable influenced by two or more other variables. Naive calculation of MR estimates in strata of the population defined by a variable affected by the risk factor can result in collider bias.Methods We propose an approach that allows MR estimation in strata of the population while avoiding collider bias. This approach constructs a new variable, the residual collider, as the residual from regression of the collider on the genetic instrument, and then calculates causal estimates in strata defined by quantiles of the residual collider. Estimates stratified on the residual collider will typically have an equivalent interpretation to estimates stratified on the collider, but they are not subject to collider bias. We apply the approach in several simulation scenarios considering different characteristics of the collider variable and strengths of the instrument. We then apply the proposed approach to investigate the causal effect of smoking on bladder cancer in strata of the population defined by bodyweight.Results The new approach generated unbiased estimates in all the simulation settings. In the applied example, we observed a trend in the stratum-specific MR estimates at different bodyweight levels that suggested stronger effects of smoking on bladder cancer among individuals with lower bodyweight.Conclusions The proposed approach can be used to perform MR studying heterogeneity among subgroups of the population while avoiding collider bias.Competing Interest StatementDG is employed part time by Novo Nordisk, outside of the submitted workFunding StatementSB is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (204623/Z/16/Z). This research was funded by United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7) and supported by the National Institute for Health Research Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. The work was partially supported by Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain (#PI18/01347), Ministerio de Ciencia e Innovacion, Spain (#PID2019-104681RB-I00). CC received a fellowship from CIBERONC, Insitituto de Salud Carlos III, Spain. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not providedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot available